ArticleTobacco induced diseases2026
Exploring causal associations between multiple smoke exposures and neuroblastoma suppressor NBL1 via Mendelian randomization.
Article in Tobacco induced diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeuroblastoma suppressor of tumorigenicity 1 (NBL1) is an established tumor suppressor and prognostic biomarker in neuroblastoma (NB). Although tobacco exposure is a well-known carcinogenic factor, its potential effect on NBL1 expression remains unclear. This two-sample Mendelian randomization (MR) study aimed to explore potential links between diverse smoking exposures, circulating NBL1 levels and NB risk.
methodsThis study performed a two-sample MR analysis to investigate the causal effects of maternal smoking around birth (66 single-nucleotide polymorphisms, SNPs), household smoking exposure (17 SNPs), and smoking initiation (37 SNPs) on circulating NBL1 levels using large-scale GWAS summary statistics. Causal estimates were obtained using IVW, weighted median, and MR-Egger methods, with sensitivity, reverse MR, and validation analyses conducted to assess robustness and directionality.
resultsNo evidence of a causal association was observed between maternal smoking around birth or household smoking exposure and NBL1 levels. In contrast, genetically predicted smoking initiation was associated with lower NBL1 expression (IVW: OR=0.70; 95% CI: 0.50-0.99, p=0.04). The weighted median method failed to reach statistical significance (OR=0.642; 95% CI: 0.40-1.04, p=0.07), whereas MR-Egger regression yielded a non-significant estimate (OR=0.39; 95% CI: 0.06-2.56, p=0.34). Sensitivity analyses indicated no substantial pleiotropy or influential outliers. Reverse MR analysis provided no evidence that NBL1 influences smoking behavior. Additional validation analyses showed no causal association between smoking initiation and NB risk.
conclusionsPrenatal and household smoking exposures do not appear to affect NBL1 expression. Genetically predicted smoking initiation was associated with reduced NBL1 expression, but not with neuroblastoma risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.